Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib With or Without Chemotherapy in EGFR-Mutated Advanced NSCLC
NCT04035486Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04035486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035486.